Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050856 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL13050822 | 0.87 | HTR2C (0.54) | SLC6A4HTR2C | |
| SCHEMBL13050838 | 0.87 | HTR2C (0.54) | SLC6A4HTR2C | |
| SCHEMBL13080885 | 0.86 | HTR2C (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL13050939 | 0.85 | HTR2A (0.46) | HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL13050935 | 0.85 | HTR2A (0.46) | HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL13050876 | 0.84 | HTR2A (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL13050879 | 0.84 | HTR2A (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL13050908 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL13050909 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009036275-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS | LINK MEDICINE CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | SLC6A2 19/4885SLC6A4 44/4885SLC6A3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.